ZYNE Zynerba Pharmaceuticals, Inc. Stock Quote

ZYNE [NASD]

Healthcare | Drug Manufacturers - Specialty & Generic | USA

Index	-	P/E	-	EPS (ttm)	-2.08	Insider Own	7.11%	Shs Outstand	29.24M	Perf Week	-1.92%
Market Cap	107.19M	Forward P/E	-	EPS next Y	-1.21	Insider Trans	0.00%	Shs Float	27.35M	Perf Month	4.07%
Income	-52.40M	PEG	-	EPS next Q	-0.33	Inst Own	22.10%	Short Float	15.49%	Perf Quarter	0.28%
Sales	-	P/S	-	EPS this Y	42.60%	Inst Trans	11.77%	Short Ratio	4.59	Perf Half Y	-2.19%
Book/sh	2.28	P/B	1.57	EPS next Y	36.60%	ROA	-63.80%	Target Price	-	Perf Year	-35.73%
Cash/sh	2.15	P/C	1.67	EPS next 5Y	-	ROE	-74.20%	52W Range	2.55 - 7.45	Perf YTD	8.48%
Dividend	-	P/FCF	-	EPS past 5Y	-17.80%	ROI	-	52W High	-51.95%	Beta	2.82
Dividend %	-	Quick Ratio	7.10	Sales past 5Y	-	Gross Margin	-	52W Low	40.39%	ATR	0.19
Employees	28	Current Ratio	7.10	Sales Q/Q	-	Oper. Margin	-	RSI (14)	48.04	Volatility	5.74% 4.79%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-268.60%	Profit Margin	-	Rel Volume	1.56	Prev Close	3.58
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	922.57K	Price	3.58
Recom	2.00	SMA20	3.60%	SMA50	-6.89%	SMA200	-11.37%	Volume	1,441,550	Change	0.00%

Dec-21-20

Reiterated

H.C. Wainwright

Buy

$12 → $9

Jul-01-20

Downgrade

Needham

Buy → Hold

Dec-31-19

Resumed

ROTH Capital

Buy

$12

Oct-21-19

Initiated

Needham

Buy

$18

Apr-22-19

Resumed

Canaccord Genuity

Buy

Feb-01-18

Resumed

H.C. Wainwright

Buy

$23

Jan-29-18

Initiated

Ladenburg Thalmann

Buy

$25.50

Jan-26-18

Initiated

Seaport Global Securities

Buy

$16

Oct-02-17

Upgrade

Cantor Fitzgerald

Neutral → Overweight

$4 → $17

Sep-29-17

Upgrade

Piper Jaffray

Neutral → Overweight

Aug-15-17

Upgrade

ROTH Capital

Neutral → Buy

Aug-15-17

Downgrade

Oppenheimer

Outperform → Perform

Aug-15-17

Downgrade

Jefferies

Buy → Hold

Aug-08-17

Downgrade

ROTH Capital

Buy → Neutral

Aug-08-17

Downgrade

H.C. Wainwright

Buy → Neutral

Aug-07-17

Downgrade

Piper Jaffray

Overweight → Neutral

Aug-07-17

Downgrade

Maxim Group

Buy → Hold

Aug-07-17

Downgrade

Cantor Fitzgerald

Overweight → Neutral

$28 → $4

Mar-28-17

Reiterated

H.C. Wainwright

Buy

$22 → $30

Feb-24-17

Initiated

Maxim Group

Buy

$32

Jan-04-21 07:30AM	Zynerba Pharmaceuticals to Present at Two January Virtual Investor Conferences GlobeNewswire
Dec-23-20 05:30AM	Here's What We Think About Zynerba Pharmaceuticals' (NASDAQ:ZYNE) CEO Pay Simply Wall St.
Dec-17-20 08:10AM	The Daily Biotech Pulse: MacroGenics Breast Cancer Drug Wins FDA Approval, Adcom Test Awaits Moderna, Virios To Make Wall Street Debut Benzinga -16.51%
06:30AM	Zynerba Pharmaceuticals Provides Regulatory Update on Zygel in Fragile X Syndrome GlobeNewswire
Dec-09-20 03:49PM	Shuman, Glenn & Stecker Investigates Zynerba Pharmaceuticals, Inc. Business Wire
Dec-08-20 06:00AM	SHAREHOLDER ALERT: Barr Law Group Investigating the Officers and Directors of EQT, ZYNE, NKTR, and FMO; Shareholders are Encouraged to Contact the Firm GlobeNewswire
Dec-07-20 12:00PM	The Law Offices of Frank R. Cruz Announces Investigation of Zynerba Pharmaceuticals (ZYNE) on Behalf of Investors Business Wire
Dec-04-20 11:30AM	Zynerba Pharmaceuticals Presents New Data in Two Posters at the 2020 Annual Meeting of the American Epilepsy Society (AES) GlobeNewswire
Dec-03-20 09:27PM	Is Zynerba Pharmaceuticals (ZYNE) A Good Stock To Buy Now? Insider Monkey
Nov-23-20 11:45AM	Zynerba Pharmaceuticals Announces the Acceptance of Two Posters at the 2020 Virtual Annual Meeting of the American Epilepsy Society (AES) GlobeNewswire
Nov-09-20 11:20AM	Earnings Update: Aurora, Canopy Growth, Canopy Rivers And Zynerba Each Post Results Benzinga
06:45AM	Zynerba Pharmaceuticals Reports Third Quarter 2020 Financial Results and Operational Highlights GlobeNewswire
Oct-16-20 11:01AM	Canaccord Predicts Over 100% Rally for These 3 Strong Buy Stocks TipRanks
02:55AM	Zynerba Up 6% As Zygel Shows Promise In Autism Trial SmarterAnalyst
Oct-15-20 03:06PM	Zynerba Pharmaceuticals Presents Data Supporting FMR1 Methylation Status as a Correlate to Fragile X Syndrome Severity at the Virtual Joint 16th International Child Neurology Congress (ICNC) & 49th Annual Child Neurology Society (CNS) Meeting GlobeNewswire +6.44%
03:05PM	New Data Describing Statistically Significant Results from the Phase 2 BRIGHT Trial in Patients with Autism Spectrum Disorder (ASD) Presented at the Virtual Joint 16th International Child Neurology Congress (ICNC) & 49th Annual Child Neurology Society (CNS) Meeting GlobeNewswire
Oct-08-20 08:32AM	Zynerba Pharmaceuticals Announces Oral Presentations at the Virtual American Academy of Child and Adolescent Psychiatry (AACAP) 2020 Annual Meeting GlobeNewswire
08:30AM	Zynerba Pharmaceuticals Announces the Acceptance of Two Posters at the Virtual Joint 49th Annual Child Neurology Society & 16th International Child Neurology Society Congress (CNS-ICNA) Meeting GlobeNewswire
Sep-23-20 02:37PM	We're Keeping An Eye On Zynerba Pharmaceuticals' (NASDAQ:ZYNE) Cash Burn Rate Simply Wall St. -7.14%
Sep-18-20 08:51AM	Zynerba Pharmaceuticals (ZYNE) Jumps: Stock Rises 7.7% Zacks
Sep-17-20 01:55PM	Zynerba Pharmaceuticals Receives Orphan Drug Designation for Cannabidiol for the Treatment of 22q11.2 Deletion Syndrome GlobeNewswire +7.65%
Sep-14-20 06:55AM	Zynerba Pharmaceuticals Provides Update on Recent Milestones GlobeNewswire
Sep-10-20 07:30AM	Zynerba Pharmaceuticals to Present at Two Upcoming Virtual Investor Conferences GlobeNewswire
Aug-10-20 06:45AM	Zynerba Pharmaceuticals Reports Second Quarter 2020 Financial Results and Operational Highlights GlobeNewswire
Aug-06-20 07:00AM	Zynerba Pharmaceuticals to Present at the Virtual 40th Annual Canaccord Genuity Growth Conference GlobeNewswire
Jul-29-20 05:50PM	Zynerba Pharmaceuticals (ZYNE) Outpaces Stock Market Gains: What You Should Know Zacks
Jul-24-20 10:16AM	What's in the Cards for Zynerba (ZYNE) This Earnings Season? Zacks
Jul-22-20 06:50AM	Zynerba Pharmaceuticals to Present an Update on the Zygel Development Program at the 17th NFXF International Fragile X Conference Research Roundup GlobeNewswire
Jul-05-20 02:00PM	The Week In Cannabis: Stocks Underperform Broader Market, Bad News For Zynerba, Organigram And More Benzinga
Jul-01-20 09:36AM	Zynerba's Zygel Fails in Phase III Fragile X Syndrome Study Zacks +9.94%
Jun-30-20 07:57AM	Zynerba's cannabis-based drug for rare genetic disorder fails study Reuters -48.47%
07:41AM	The Daily Biotech Pulse: Verrica Flags Potential Regulatory Delay, Back-To-Back FDA Approvals For Merck's Keytruda, OncoCyte Stalls Lung Nodule Malignancy Test Benzinga
06:45AM	Zynerba Pharmaceuticals Announces Top Line Results from Pivotal CONNECT-FX Trial of Zygel (CBD Gel) in Fragile X Syndrome GlobeNewswire
Jun-29-20 08:57AM	Implied Volatility Surging For Zynerba Pharmaceuticals (ZYNE) Stock Options Zacks
Jun-25-20 11:26AM	Zacks Market Edge Highlights: Canopy Growth, Aurora Cannabis, Hexo, GW Pharmaceuticals and Zynerba Zacks
Jun-17-20 09:43AM	3 Pharmaceutical Stocks With Major Catalysts Approaching TipRanks
Jun-15-20 08:53PM	Zynerba Pharmaceuticals Inc (ZYNE): Hedge Funds Are Nibbling Insider Monkey
May-27-20 06:45AM	Zynerba Pharmaceuticals Announces Positive Top Line Results from Exploratory Open Label Phase 2 BRIGHT Trial of Zygel in Autism Spectrum Disorder GlobeNewswire -9.69%
May-26-20 06:52AM	Zynerba Pharmaceuticals Announces New Two-Year Data from Open Label Extension of the Phase 2 FAB-C Trial in Patients with Fragile X at 2020 American Academy of Neurology (AAN) Science Highlights Virtual Session GlobeNewswire
06:50AM	Zynerba Pharmaceuticals Announces Presentation of Phase 2 BELIEVE Safety, Efficacy and Quality of Life Data in Developmental and Epileptic Encephalopathies (DEE) at the 2020 American Academy of Neurology (AAN) Science Highlights Virtual Session GlobeNewswire
May-25-20 11:30AM	Is Zynerba Pharmaceuticals (ZYNE) Stock Outpacing Its Medical Peers This Year? Zacks
May-22-20 07:30AM	Zynerba Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference GlobeNewswire +18.14%
May-21-20 08:00AM	Zynerba Pharmaceuticals Changes Annual Meeting of Shareholders to Virtual-Only Format in Response to COVID-19 Pandemic GlobeNewswire
May-11-20 06:50AM	Zynerba Pharmaceuticals Reports First Quarter 2020 Financial Results and Operational Highlights GlobeNewswire +11.53%
Apr-28-20 01:01PM	How Much is Zynerba Pharmaceuticals, Inc.'s (NASDAQ:ZYNE) CEO Getting Paid? Simply Wall St.
Apr-10-20 08:00AM	Zynerba Pharmaceuticals to Present at the 19th Annual Needham Virtual Healthcare Conference GlobeNewswire
Apr-02-20 05:45PM	Zynerba Pharmaceuticals (ZYNE) Gains But Lags Market: What You Should Know Zacks
Mar-25-20 05:50PM	Zynerba Pharmaceuticals (ZYNE) Gains But Lags Market: What You Should Know Zacks
Mar-10-20 06:50AM	Zynerba Pharmaceuticals Reports Fourth Quarter and Year End 2019 Financial Results and Operational Highlights GlobeNewswire +10.40%
Mar-09-20 08:30AM	Zynerba Pharmaceuticals Announces Poster Presentations at the American Academy of Neurology (AAN) 2020 Annual Meeting GlobeNewswire -13.93%
Mar-05-20 08:30AM	Zynerba Pharmaceuticals to Present at the 32nd Annual ROTH Conference GlobeNewswire
Mar-03-20 12:08PM	Zynerba Pharmaceuticals Presents Data Showing that the Baseline Characteristics of Patients in Phase 2 BRIGHT Trial in Autism Spectrum Disorder Indicate a Moderate-to-Severe Study Population GlobeNewswire
12:07PM	Zynerba Pharmaceuticals Presents Health State Utility Index Data on Severity of Fragile X Syndrome (FXS) and Diagnostic Challenges Faced by Caregivers GlobeNewswire
Mar-02-20 05:45PM	Zynerba Pharmaceuticals (ZYNE) Stock Sinks As Market Gains: What You Should Know Zacks
Feb-26-20 08:49AM	What's in the Cards for Zynerba (ZYNE) This Earnings Season? Zacks -8.47%
06:50AM	Zynerba Pharmaceuticals Announces the Completion of Enrollment in the Pivotal CONNECT-FX Trial of Zygel in Fragile X Syndrome GlobeNewswire
Feb-25-20 11:21AM	Zynerba Pharmaceuticals, Inc.'s (NASDAQ:ZYNE) Path To Profitability Simply Wall St. +7.13%
07:15AM	Zynerba Pharmaceuticals Receives New U.S. Patent for Treatment of Autism Spectrum Disorder with Purified Cannabidiol GlobeNewswire
Feb-20-20 08:30AM	Zynerba Pharmaceuticals Announces Presentations at the American Society for Experimental Neurotherapeutics (ASENT) 2020 Annual Meeting GlobeNewswire
Feb-18-20 09:07AM	Zynerba Pharmaceuticals Enters Oversold Territory Zacks +8.46%
Feb-10-20 05:45PM	Zynerba Pharmaceuticals (ZYNE) Gains But Lags Market: What You Should Know Zacks
08:05AM	3 Strong Buy Healthcare Stocks With Triple-Digit Upside TipRanks
Feb-03-20 05:45PM	Zynerba Pharmaceuticals (ZYNE) Stock Sinks As Market Gains: What You Should Know Zacks
06:45AM	Zynerba Pharmaceuticals Announces Achievement of Patient Screening Target for Pivotal Trial of Zygel in Fragile X Syndrome GlobeNewswire
Jan-31-20 03:45PM	Top Marijuana Stocks on the NASDAQ Investopedia
Jan-28-20 05:45PM	Zynerba Pharmaceuticals (ZYNE) Stock Sinks As Market Gains: What You Should Know Zacks
Jan-14-20 05:50PM	Zynerba Pharmaceuticals (ZYNE) Dips More Than Broader Markets: What You Should Know Zacks
Jan-13-20 09:15AM	A Hectic but Positive First Full Week of 2020 Zacks
06:50AM	Zynerba Pharmaceuticals Announces that Enrollment is Nearing Completion in Pivotal CONNECT-FX Trial in Fragile X Syndrome GlobeNewswire
06:45AM	Zynerba Pharmaceuticals Announces Achievement of Enrollment Target in Phase 2 Trial of Zygel in Autism Spectrum Disorder GlobeNewswire
Jan-08-20 10:38AM	Easy Come, Easy Go: How Zynerba Pharmaceuticals (NASDAQ:ZYNE) Shareholders Got Unlucky And Saw 71% Of Their Cash Evaporate Simply Wall St.
Dec-23-19 12:10PM	FINAL DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Zynerba Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $50,000 to Contact the Firm ACCESSWIRE
10:12AM	FINAL DEADLINE ALERT - Zynerba Pharmaceuticals, Inc. (ZYNE) - Bronstein, Gewirtz & Grossman, LLC Reminds Investors With Losses Exceeding $100K of Class Action and Lead Deadline: December 23, 2019 ACCESSWIRE
10:00AM	ZYNE FINAL DEADLINE: ROSEN LAW FIRM Reminds Zynerba Pharmaceuticals, Inc. Investors of Important Deadline Today in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm ZYNE GlobeNewswire
09:36AM	MONDAY DEADLINE REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Zynerba Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm Business Wire
09:34AM	Ride the Cannabis Wave With These 3 Stocks Zacks
Dec-22-19 09:23PM	DEADLINE TOMORROW: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Zynerba Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
05:08PM	Do Hedge Funds Love Zynerba Pharmaceuticals Inc (ZYNE)? Insider Monkey
02:21PM	The Week In Cannabis: Federal Spending Bill, Vaping Bans And More Corporate Carnage Benzinga
Dec-20-19 05:20PM	FINAL DEADLINE MONDAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Zynerba Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
04:01PM	MONDAY DEADLINE ALERT: The Schall Law Firm Announces it is Investigating Claims Against Zynerba Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm Business Wire
11:35AM	The Zacks Analyst Blog Highlights: Uber, AES, CIRCOR International, Edwards Lifesciences and Zynerba Pharmaceuticals Zacks
10:00AM	UPCOMING DEADLINE ALERT - Zynerba Pharmaceuticals, Inc. (ZYNE) - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action and Lead Deadline: December 23, 2019 GlobeNewswire
Dec-19-19 02:01PM	Uber Is Formally into the Staffing Business Zacks +6.83%
01:32PM	Zynerba Shareholder Notice: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Zynerba Pharmaceuticals, Inc. To Contact The Firm Newsfile
08:06AM	New Strong Buy Stocks for December 19th Zacks
Dec-18-19 04:16PM	Pawar Law Group Reminds Investors of December 23 Deadline in Securities Class Action Lawsuit Against Zynerba Pharmaceuticals, Inc. ZYNE GlobeNewswire -6.24%
12:57PM	Zynerba Shareholder Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Zynerba Pharmaceuticals, Inc. To Contact The Firm Newsfile
12:28PM	Pot Stock Short-Sellers Net Almost $1 Billion in 2019 Bloomberg
Dec-17-19 02:07PM	SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Zynerba Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline ZYNE GlobeNewswire
01:43PM	Zynerba Deadline Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Zynerba Pharmaceuticals, Inc. To Contact The Firm Newsfile
Dec-16-19 05:12PM	Zynerba Analyst Says Stock A Buy Ahead Of Zygel Data Release In 2020 Benzinga +13.49%
11:19AM	Zynerba Shareholder Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Zynerba Pharmaceuticals, Inc. To Contact The Firm Newsfile
10:39AM	UPCOMING DEADLINE ALERT - Zynerba Pharmaceuticals, Inc. (ZYNE) - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action and Lead Deadline: December 23, 2019 ACCESSWIRE
07:05AM	New Strong Buy Stocks for December 16th Zacks
Dec-13-19 10:00AM	iRobot Corporation (IRBT), Zendesk, Inc. (ZEN) & Zynerba Pharmaceuticals, Inc. (ZYNE)- Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Actions GlobeNewswire
Dec-12-19 10:23AM	Zynerba Deadline Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Zynerba Pharmaceuticals, Inc. To Contact The Firm Newsfile
Dec-11-19 08:19PM	SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Zynerba Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline ZYNE GlobeNewswire
04:31PM	ZYNE DEADLINE: Zhang Investor Law Reminds Investors of December 23 Deadline in Securities Class Action Lawsuit Against Zynerba Pharmaceuticals, Inc. ZYNE GlobeNewswire
04:30PM	Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Infosys, Zynerba, iRobot, and Zendesk and Encourages Investors to Contact the Firm PR Newswire

Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. It focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. The company is developing Zygel, a transdermal cannabidiol gel, which is in Phase II clinical trial for treating children and adolescent patients with developmental and epileptic encephalopathies; is in Phase II clinical trial for treating children and adolescent patients with autism spectrum disorder; is in Phase II clinical trial for treating pediatric behavioral and emotional symptoms of 22q11.2 deletion syndrome; and to treat children and adolescent patients with fragile X syndrome. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Devon, Pennsylvania.

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience